Skip Navigation



JAC Advance Access published online on January 9, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl497
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/3/565    most recent
dkl497v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marucco, D. A.
Right arrow Articles by Di Perri, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marucco, D. A.
Right arrow Articles by Di Perri, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

D. Aguilar Marucco*, L. Veronese, D. Gonzalez de Requena, S. Bonora, A. Calcagno, I. Cavecchia, A. Sinicco, F. G. De Rosa, G. Cariti and G. Di Perri

Department of Infectious Diseases, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera 164, Turin, Italy

Received 12 September 2006; returned 29 October 2006; revised 9 November 2006; accepted 13 November 2006

* Corresponding author. Tel: +39-011-4393980; Fax: +39-011-4393882; E-mail: diego.agui{at}libero.it

OBJECTIVES: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy.

PATIENTS AND METHODS: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy.

RESULTS: We observed a significant HIV-RNA decrease (>1 log10 copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose.

CONCLUSIONS: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.

Key Words: anti-HIV activity , interferons , anti-HCV therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
D. Vendrame, M. Sourisseau, V. Perrin, O. Schwartz, and F. Mammano
Partial Inhibition of Human Immunodeficiency Virus Replication by Type I Interferons: Impact of Cell-to-Cell Viral Transfer
J. Virol., October 15, 2009; 83(20): 10527 - 10537.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.